Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Chromadex Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CDXC
Nasdaq
8731
https://chromadex.com/default.aspx
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Chromadex Corp
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
- Apr 25th, 2024 12:34 pm
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- Apr 24th, 2024 12:34 pm
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
- Apr 23rd, 2024 12:32 pm
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
- Apr 5th, 2024 11:43 am
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
- Apr 2nd, 2024 10:48 am
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
- Mar 26th, 2024 12:32 pm
ChromaDex Full Year 2023 Earnings: EPS Beats Expectations
- Mar 8th, 2024 10:16 am
ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA
- Mar 7th, 2024 6:59 pm
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 3:37 pm
Q4 2023 Chromadex Corp Earnings Call
- Mar 7th, 2024 11:27 am
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
- Mar 6th, 2024 9:04 pm
Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company
- Mar 2nd, 2024 2:00 pm
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
- Feb 21st, 2024 1:32 pm
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
- Feb 5th, 2024 1:32 pm
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
- Jan 26th, 2024 9:08 pm
ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit
- Jan 19th, 2024 1:40 pm
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
- Dec 20th, 2023 2:04 pm
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
- Dec 12th, 2023 3:30 pm
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
- Nov 30th, 2023 1:34 pm
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued
- Nov 28th, 2023 10:38 am
Scroll